Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Kymera Therapeutics

05/08/2026 14:31

Kymera Therapeutics, Inc. KYMR.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -95 cents.  The mean expectation of twenty three analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from $-1.42 to -27 cents per share.
Revenue rose 466.4% to $65.00 million from a year ago; analysts expected $31.17 million. 
Kymera Therapeutics, Inc.'s reported EPS for the quarter was a loss of 62 cents​.
The company reported a quarterly loss of $61.21 million.
Kymera Therapeutics, Inc. shares had fallen by 9.0% this quarter and gained 34.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.6% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." 
This summary was machine generated from LSEG data August 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.71
-0.62
Beat
Mar. 31 2026 
-0.88
-0.71
Beat
Dec. 31 2025 
-0.80
-0.97
Missed
Sep. 30 2025 
-0.80
-0.94
Missed